NAYA生物科学与INVO生物科学合并,形成肿瘤学、自体免疫和生育组合组合。 NAYA Biosciences merges with INVO Bioscience, creating a combined oncology, autoimmune, and fertility portfolio.

INVO生物科学和NAYA生物科学合并,组成了一家名为NAYA生物科学的新公司(NASDAQ:NAYA)。 INVO Bioscience and NAYA Biosciences have merged, forming a new company named NAYA Biosciences (NASDAQ: NAYA). 合并的目的是增加病人获得肿瘤病和自动免疫疾病创新治疗的机会,同时维持现有的创收生育业务。 This merger aims to enhance patient access to innovative treatments for oncology and autoimmune diseases, while maintaining the existing revenue-generating fertility business. 合并后的实体将扩大其投资组合,包括生育,瘤和自身免疫领域的临床阶段资产. The combined entity will broaden its portfolio to include clinical-stage assets across fertility, oncology, and autoimmune sectors.